Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2014 2
2015 2
2017 3
2018 6
2019 6
2020 8
2021 6
2022 8
2023 11
2024 12
2025 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Response assessment criteria for brain metastases: proposal from the RANO group.
Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Lin NU, et al. Lancet Oncol. 2015 Jun;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27. Lancet Oncol. 2015. PMID: 26065612 Review.
The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases. ...
The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effo …
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults.
Ellingson BM, Sanvito F, Cloughesy TF, Huang RY, Villanueva-Meyer JE, Pope WB, Barboriak DP, Shankar LK, Smits M, Kaufmann TJ, Boxerman JL, Weller M, Galanis E, Groot J, Gilbert MR, Lassman AB, Shiroishi MS, Nabavizadeh A, Mehta M, Stupp R, Wick W, Reardon DA, Vogelbaum MA, van den Bent M, Chang SM, Wen PY. Ellingson BM, et al. AJNR Am J Neuroradiol. 2024 Dec 9;45(12):1846-1856. doi: 10.3174/ajnr.A8396. AJNR Am J Neuroradiol. 2024. PMID: 38926092 Review.
Recently, an updated version of the Response Assessment in Neuro-Oncology (RANO) criteria (RANO 2.0) was developed to improve upon prior criteria and provide an updated, standardized framework for assessing treatment response in clinical trials for gliomas in adults …
Recently, an updated version of the Response Assessment in Neuro-Oncology (RANO) criteria (RANO 2.0) was developed to improve …
RANO criteria for response assessment of brain metastases based on amino acid PET imaging.
Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, Koh ES, Law I, Le Rhun E, Mair MJ, Werner JM, Berghoff AS, Furtner J, Minniti G, Scott AM, Short SC, Ivanidze J, Johnson DR, Suchorska B, Tolboom N, Tonn JC, Verger A, Galanis E, Brastianos PK, Wen PY, Weller M, Lin NU, Preusser M. Albert NL, et al. Nat Med. 2025 May;31(5):1424-1430. doi: 10.1038/s41591-025-03633-7. Epub 2025 May 8. Nat Med. 2025. PMID: 40341837 Review.
Here, we define the PET Response Assessment in Neuro-Oncology (RANO) for brain metastasis (BM) 1.0 criteria for metabolic response assessment of brain metastases using amino acid PET. By introducing an innovative endpoint for next-generation clinical trials, the PET …
Here, we define the PET Response Assessment in Neuro-Oncology (RANO) for brain metastasis (BM) 1.0 criteria for metabolic resp …
Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria.
Douri K, Iorio-Morin C, Mercure-Cyr R, Figueiredo G, Touchette CJ, Masson-Côté L, Mathieu D. Douri K, et al. Curr Oncol. 2023 Oct 24;30(11):9382-9391. doi: 10.3390/curroncol30110679. Curr Oncol. 2023. PMID: 37999099 Free PMC article.
This study's goal was to validate the RANO-BM criteria thresholds for tumor progression in a cohort of patients with brain metastases managed using SRS. ...CONCLUSIONS: Current RANO-BM criteria unreliably identifies clinically relevant tumor progressio …
This study's goal was to validate the RANO-BM criteria thresholds for tumor progression in a cohort of patients with brain met …
Effect of MRI-based semiautomatic size-assessment in cerebral metastases on the RANO-BM classification.
Bauknecht HC, Klingebiel R, Hein P, Wolf C, Bornemann L, Siebert E, Bohner G. Bauknecht HC, et al. Clin Neuroradiol. 2020 Jun;30(2):263-270. doi: 10.1007/s00062-019-00785-1. Epub 2019 Jun 13. Clin Neuroradiol. 2020. PMID: 31197388
The response assessment in neuro-oncology (RANO) criteria for brain metastases (RANO-BM) were applied by means of a software (autoRANO-BM) as well as manually (manRANO-BM) at an interval of 3 weeks. ...In 14 cases with suspected disease progress …
The response assessment in neuro-oncology (RANO) criteria for brain metastases (RANO-BM) were applied by means of a sof …
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.
Vaz Batista M, Pérez-García JM, Cortez P, Garrigós L, Fernández-Abad M, Gion M, Martínez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodríguez J, Martrat G, Pérez-Escuredo J, Alcalá-López D, Sampayo-Cordero M, Braga S, Cortés J, Llombart-Cussac A. Vaz Batista M, et al. ESMO Open. 2024 Sep;9(9):103699. doi: 10.1016/j.esmoop.2024.103699. Epub 2024 Sep 9. ESMO Open. 2024. PMID: 39255534 Free PMC article. Clinical Trial.
The primary endpoint was intracranial objective response rate per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) for both cohorts. RESULTS: Intracranial objective response rate per RANO-BM was 50.0% [3/6 patients; 95% confidence inter …
The primary endpoint was intracranial objective response rate per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM …
PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study.
Kaur M, Cassinelli Petersen G, Jekel L, von Reppert M, Varghese S, Dixe de Oliveira Santo I, Avesta A, Aneja S, Omuro A, Chiang V, Aboian M. Kaur M, et al. Cancers (Basel). 2023 Sep 30;15(19):4822. doi: 10.3390/cancers15194822. Cancers (Basel). 2023. PMID: 37835516 Free PMC article.
In this study, we aimed to compare volumetric changes of edema to RANO-BM-based measurements of contrast-enhancing lesion size. Patients with NSCLC METS 10 mm on post-contrast T1-weighted image and treated with SRT had measurements for up to seven follow-up scans us …
In this study, we aimed to compare volumetric changes of edema to RANO-BM-based measurements of contrast-enhancing lesion size …
PET imaging in patients with brain metastasis-report of the RANO/PET group.
Galldiks N, Langen KJ, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, Weller M, Tonn JC. Galldiks N, et al. Neuro Oncol. 2019 May 6;21(5):585-595. doi: 10.1093/neuonc/noz003. Neuro Oncol. 2019. PMID: 30615138 Free PMC article. Review.
Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. ...The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contra …
Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. ...The use of systemic treatm …
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, Fan Y, Shi J, Zhang G, Cui J, Zhou J, Song Y, Zhuang W, Ma Z, Hu Y, Li G, Dong X, Feng J, Lu S, Wu J, Li J, Zhang L, Wang D, Xu X, Yang TY, Yang N, Guo Y, Zhao J, Yao Y, Zhong D, Xia B, Yang CT, Zhu B, Sun P, Shim BY, Chen Y, Wang Z, Ahn MJ, Wang J, Wu YL. Zhou Q, et al. Med. 2025 Jan 10;6(1):100513. doi: 10.1016/j.medj.2024.09.002. Epub 2024 Oct 9. Med. 2025. PMID: 39389055 Clinical Trial.
Zorifertinib significantly prolonged intracranial PFS versus control (BICR per modified RECIST1.1: HR, 0.467; 95% CI, 0.352-0.619; investigator per RANO-BM: HR, 0.627; 95% CI, 0.466-0.844). Overall survival (OS) was immature; the estimated median OS was 37.3 months …
Zorifertinib significantly prolonged intracranial PFS versus control (BICR per modified RECIST1.1: HR, 0.467; 95% CI, 0.352-0.619; investiga …
73 results